Evidence map›Paper›PMID 29046310›Full record

ReviewClinical and vaccine immunology : CVI2017

Protein Structure Facilitates High-Resolution Immunological Mapping.

Madison Zuverink, Joseph T Barbieri

Open access · diamondAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Clinical and vaccine immunology : CVI, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Madison ZuverinkMicrobiology and Immunology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Joseph T BarbieriMicrobiology and Immunology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA jtb01@mcw.edu.
Medical College of Wisconsin · US

Funding

Mechanisms of Bacterial Toxin ActionR01AI030162 · NIAID · MEDICAL COLLEGE OF WISCONSIN · PI BARBIERI, JOSEPH T · 1990 to 2019
$6.7M
Vaccines Against BotulismR01AI118389 · NIAID · MEDICAL COLLEGE OF WISCONSIN · PI BARBIERI, JOSEPH T, PELLETT, SABINE · 2015 to 2024
$6.1M
NIAID NIH HHS R01 AI030162NIAID NIH HHS R01 AI118389
6 · The paper itself

Abstract

Select agents (SA) pose unique challenges for licensing vaccines and therapies. In the case of toxin-mediated diseases, HHS assigns guidelines for SA use, oversees vaccine and therapy development, and approves animal models and approaches to identify mechanisms for toxin neutralization. In this commentary, we discuss next-generation vaccines and therapies against ricin toxin and botulinum toxin, which are regulated SA toxins that utilize structure-based approaches for countermeasures to guide rapid response to future biothreats.

Indexed as

AnimalsBotulinum ToxinsBotulismCrystallography, X-RayHumansModels, MolecularPoisoningProtein ConformationRicinVaccinesBotulinum ToxinsRicinVaccinesantibodiesbotulinum toxinmass spectrometryricinRiVaxRTARVEc

Identifiers

PMID29046310
PMCPMC5717179
OpenAlexW2766855647

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.